View Future GrowthKaken Pharmaceutical 과거 순이익 실적과거 기준 점검 0/6Kaken Pharmaceutical 의 수입은 연평균 -12.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 3.2%의 비율로 증가해 왔습니다.핵심 정보-12.22%순이익 성장률-11.89%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률3.16%자기자본이익률-2.63%순이익률-5.06%다음 순이익 업데이트13 May 2026최근 과거 실적 업데이트공시 • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026공시 • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026공시 • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026공시 • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025공시 • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025공시 • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025모든 업데이트 보기Recent updates공시 • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026공시 • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.공시 • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026공시 • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026공시 • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.공시 • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025공시 • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025공시 • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.공시 • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.공시 • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.공시 • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025공시 • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.공시 • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to공시 • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025공시 • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024공시 • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024공시 • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.공시 • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024공시 • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024공시 • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.공시 • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)공시 • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023공시 • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.공시 • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023공시 • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.공시 • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023매출 및 비용 세부 내역Kaken Pharmaceutical가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:KKPC.F 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Dec 2575,662-3,83219,91923,81330 Sep 2582,01965119,65624,42430 Jun 2594,64812,46218,67321,10931 Mar 2594,03513,94518,50118,72531 Dec 2493,34920,52516,89214,59830 Sep 2487,24518,24316,24612,77830 Jun 2472,1487,26916,30612,94131 Mar 2472,0448,02516,16512,54331 Dec 2372,0962,96616,10217,98130 Sep 2372,3363,54416,09717,19730 Jun 2372,9375,04315,68516,35931 Mar 2372,9845,44015,47615,78931 Dec 2273,8998,45215,5978,69530 Sep 2275,2658,79215,7268,74230 Jun 2275,7789,09415,7978,58531 Mar 2276,0349,54915,8338,42031 Dec 2175,60512,71716,2587,90930 Sep 2175,77812,90016,2707,47730 Jun 2175,36212,94716,3617,02831 Mar 2174,97913,40516,1556,73631 Dec 2076,13614,75016,1596,53930 Sep 2080,85117,04916,3476,35130 Jun 2084,96718,36416,5906,38231 Mar 2089,23219,37017,3206,41831 Dec 1991,75919,08217,7157,25830 Sep 1991,81418,48218,0587,88730 Jun 1992,36518,56618,4978,29131 Mar 1994,16517,77518,72410,26131 Dec 1894,12316,43119,41310,11830 Sep 1896,09117,01519,67210,21630 Jun 1897,59817,61519,9529,89531 Mar 1898,43019,04320,1748,15231 Dec 1799,40520,89319,8277,24330 Sep 1799,16021,43919,8546,46730 Jun 17100,21821,68419,9436,38731 Mar 17101,47922,01720,0206,45031 Dec 16103,26418,99220,2906,47630 Sep 16106,93620,10620,3026,54530 Jun 16108,32520,63920,1916,37431 Mar 16109,73021,14320,3025,88331 Dec 15108,16522,65120,0777,20130 Sep 15104,63018,96620,2207,20630 Jun 15100,05815,79220,6067,403양질의 수익: KKPC.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: KKPC.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: KKPC.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 KKPC.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: KKPC.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: KKPC.F는 현재 수익성이 없으므로 자본 수익률이 음수(-2.63%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/11 13:14종가2026/01/13 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kaken Pharmaceutical Co., Ltd.는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kazuaki HashiguchiDaiwa Securities Co. Ltd.Junya YamazakiJefferies LLCToshiyuki IwataMizuho Securities Co., Ltd.6명의 분석가 더 보기
공시 • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026
공시 • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
공시 • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
공시 • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
공시 • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
공시 • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026
공시 • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
공시 • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
공시 • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
공시 • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.
공시 • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
공시 • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
공시 • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.
공시 • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.
공시 • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
공시 • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.
공시 • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to
공시 • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
공시 • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024
공시 • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024
공시 • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.
공시 • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024
공시 • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024
공시 • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.
공시 • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)
공시 • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023
공시 • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.
공시 • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023
공시 • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.
공시 • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023